Medical articles today

/* 728x15, */

30 drop in heart disease deaths in Canada over a decade

A new study in CMAJ (Canadian Medical Association Journal) reports that the rates of death and hospital admissions for cardiovascular disease declined thirty percent over a ten year period in Canada. The findings draw attention to successful efforts to prevent heart disease, the leading cause of death globally. But, for the first time, there is indication that more women than men are dying of cardiovascular causes. Data from the Canadian Mortality Database, Statistics Canada's national death registry which contains information on the cause of all deaths in the country were evaluated. The study was the first of its kind in Canada. It also analyzed hospital admissions for heart attacks, heart failure and stroke.

Finding The Best Heart Disease And Stroke Treatments For Patients With Diabetes Using New Tool

Researchers from North Carolina State University and Mayo Clinic have developed a computer model that medical doctors can use to determine the best time to begin using statin therapy in diabetes patients to help prevent heart disease and stroke. "The research is significant because patients with diabetes are at high risk for cardiovascular disease and statins are the single most commonly used treatment for patients at risk of heart disease and/or stroke, " says Dr. Brian Denton, "and this model can help determine the best course of action for individual patients based on their risk of developing cardiovascular disease." Denton is an assistant professor in NC State's Edward P.

/* 468x60, */

Heart Attack Patient Treated With Own Heart Stem Cells In Clinical Trial

Doctors at a heart center in the US announced yesterday that the first of 24 heart attack patients taking part in a clinical trial has successfully undergone a procedure where his own heart tissue was used to grow specialized heart stem cells that were then injected back into his heart where it is hoped they will repair and regenerate healthy heart muscle in place of that injured by heart attack. Doctors at the Cedars-Sinai Heart Institute in Los Angeles said that the minimally-invasive procedure was completed on the first patient, Kenneth Milles, last Friday. Milles, who is 39, works as a controller with a small construction company in San Fernando Valley.

Enzyme Doesn't Act Alone In Atrial Fibrillation

An overactive enzyme is behind a leaky calcium channel that plays a role in the development of atrial fibrillation, which is the most common cardiac arrhythmia that is responsible for a third of all strokes. However, it doesn't act alone, say researchers at Baylor College of Medicine. The findings can be found online in the current edition of the Journal of Clinical Investigation. "When the heart pumps properly, the muscle contractions are regulated by waves of calcium. When the heart relaxes, the calcium is stored; when the heart contracts, it is released, " said Dr Xander Wehrens, assistant professor of molecular physiology and biophysics, and cardiology at BCM.

Bioheart To Introduce Improved Heart Failure Monitoring Systems At Heart Failure Nurses Annual Meeting

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced that the company will be introducing its heart failure monitoring systems at the American Association of Heart Failure Nurses 5th Annual Meeting. This year's meeting will take place from June 25 - 27, 2009 at the Hyatt Regency Minneapolis in Minneapolis, Minnesota. The compact Bioheart 3370 home heart failure monitor engages patients through personalized daily interactions and questions, while collecting vital signs and transmitting the information directly into a database.

/* 468x60, */

FDA Grants LUCAS trade; 2 Chest Compression System 510 k Clearance In The United States

Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE: MDT), announced today that LUCAS™ 2, the next-generation LUCAS™ Chest Compression System, has been granted 510(k) market clearance by the U.S. Food and Drug Administration (FDA). Developed and manufactured by Jolife AB and distributed exclusively in the United States by Physio-Control, the LUCAS 2 is an automated, battery-powered device that is designed to give consistent, uninterrupted compressions to victims in cardiac arrest. Since performing manual chest compressions according to the American Heart Association guidelines is both difficult and physically demanding, Jolife created the LUCAS Chest Compression System to assist.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy